IRIS
MOR, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.041
AS - Asia 8.912
EU - Europa 8.553
SA - Sud America 1.447
AF - Africa 455
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 30.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.739
SG - Singapore 3.778
CN - Cina 2.921
IT - Italia 1.676
FI - Finlandia 1.428
IE - Irlanda 1.288
BR - Brasile 1.163
SE - Svezia 1.144
DE - Germania 903
HK - Hong Kong 755
UA - Ucraina 644
VN - Vietnam 533
NL - Olanda 348
ZA - Sudafrica 306
TR - Turchia 270
GB - Regno Unito 263
CA - Canada 200
AT - Austria 186
RU - Federazione Russa 186
IN - India 158
FR - Francia 119
AR - Argentina 107
CI - Costa d'Avorio 89
BD - Bangladesh 84
BE - Belgio 84
JP - Giappone 70
PL - Polonia 69
ES - Italia 63
MX - Messico 61
ID - Indonesia 56
KR - Corea 54
EC - Ecuador 53
CZ - Repubblica Ceca 47
IQ - Iraq 41
PK - Pakistan 32
LT - Lituania 26
VE - Venezuela 26
CO - Colombia 23
PY - Paraguay 22
CL - Cile 20
JO - Giordania 18
MA - Marocco 16
UZ - Uzbekistan 16
PE - Perù 13
AZ - Azerbaigian 12
NP - Nepal 12
UY - Uruguay 12
IL - Israele 11
KE - Kenya 11
RO - Romania 11
IR - Iran 9
SA - Arabia Saudita 9
BY - Bielorussia 8
EG - Egitto 8
ET - Etiopia 8
MY - Malesia 8
PA - Panama 8
EU - Europa 7
HN - Honduras 7
HU - Ungheria 7
OM - Oman 7
PS - Palestinian Territory 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
KG - Kirghizistan 6
NI - Nicaragua 6
SY - Repubblica araba siriana 6
BG - Bulgaria 5
BO - Bolivia 5
CH - Svizzera 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
EE - Estonia 5
HR - Croazia 5
LB - Libano 5
NO - Norvegia 5
TH - Thailandia 5
AL - Albania 4
CY - Cipro 4
DZ - Algeria 4
JM - Giamaica 4
KZ - Kazakistan 4
LU - Lussemburgo 4
MD - Moldavia 4
AU - Australia 3
BH - Bahrain 3
GY - Guiana 3
LV - Lettonia 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TJ - Tagikistan 3
AM - Armenia 2
AO - Angola 2
BW - Botswana 2
DK - Danimarca 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
Totale 30.408
Salva come PNG Salva come JPEG
Città #
Singapore 1.908
Ashburn 1.285
Chandler 1.285
Dublin 1.279
Dallas 975
Jacksonville 753
Hong Kong 744
Santa Clara 740
Beijing 732
Parma 554
Dearborn 456
Ann Arbor 440
Boardman 420
Nanjing 319
Johannesburg 289
Los Angeles 260
Princeton 248
Munich 237
New York 235
Izmir 233
Shanghai 222
Ho Chi Minh City 210
Wilmington 190
Hefei 179
San Mateo 162
Helsinki 153
Vienna 151
São Paulo 123
Toronto 114
Bremen 113
Shenyang 109
Columbus 106
Milan 105
Hanoi 99
Moscow 98
Nanchang 93
Abidjan 89
Jinan 88
Hebei 86
Kunming 84
Turku 75
Brussels 74
Buffalo 72
Bologna 71
The Dalles 69
Seattle 65
Tokyo 64
Düsseldorf 63
Changsha 60
Council Bluffs 59
Des Moines 58
London 58
Warsaw 56
Guangzhou 53
Jiaxing 49
Brooklyn 47
San Jose 47
Tianjin 47
Frankfurt am Main 46
Jakarta 46
Seoul 44
Modena 43
Phoenix 42
Pune 42
Houston 41
Montreal 40
Brescia 38
Woodbridge 38
Stockholm 34
Fremont 33
Rio de Janeiro 33
Chennai 32
Denver 31
Chicago 30
Norwalk 30
Nuremberg 30
Belo Horizonte 29
Haiphong 29
San Francisco 29
Zhengzhou 29
Orem 27
Grafing 24
Hangzhou 24
Amsterdam 23
Atlanta 23
Poplar 23
Ankara 22
Brno 22
Da Nang 22
Fuzhou 20
Campinas 19
Curitiba 19
Dong Ket 18
Ottawa 18
Porto Alegre 18
Amman 17
Boston 17
Brasília 17
Manchester 17
Mexico City 17
Totale 18.249
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 313
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 239
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 222
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 209
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 204
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 204
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 198
2-Aminobenzimidazoles as new potent H3-antagonists 197
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 196
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 192
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 191
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 190
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 187
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 186
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 185
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 185
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 183
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 181
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 180
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 175
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 172
Aminobenzimidazoles as new potent H3-antagonists 172
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 170
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 167
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 166
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 164
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 163
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 162
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 162
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 160
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 160
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 159
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 159
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 157
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 157
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 156
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 156
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 154
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 154
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 153
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 152
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 152
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 151
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 151
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 150
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 148
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 148
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 147
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 145
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 145
5-benzylidene-hydantoins as new inhibitors of cell proliferation 144
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 142
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 141
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 141
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 140
3-Aminoazetidin-2-one Derivatives asN-Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration 139
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 138
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 137
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 137
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 137
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 136
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 135
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 134
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 133
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 132
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 132
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 132
Steps towards sustainable solid phase peptide synthesis: use and recovery ofN-octyl pyrrolidone 132
Functional modulation of the human gut microbiome by bacteria vehicled by cheese 131
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 131
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 131
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 131
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 130
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 130
Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend 130
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 129
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 128
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 128
Mannich base derivatives as novel EGFR irreversible inhibitors 127
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 127
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 127
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 127
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 127
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 125
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 125
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 124
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 124
ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS 124
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 123
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 123
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 122
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 122
HPLC detection ofthioperamide from biological samples and its determination in rat blood and brainafter systemic administration 121
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 121
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 121
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 120
Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity in Vivo 120
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 120
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 120
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 120
Totale 15.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.655
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.655
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021953 0 0 0 0 0 51 206 40 341 45 213 57
2021/20221.311 24 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/20256.618 169 350 436 424 600 739 303 354 836 650 590 1.167
2025/20268.642 1.235 1.584 1.832 1.405 1.951 635 0 0 0 0 0 0
Totale 30.806